Olympus launches new SeleCT Screening campaign
| Stock | 4DMEDICAL Ltd (4DX.ASX) |
|---|---|
| Release Time | 11 Jun 2025, 8:51 a.m. |
| Price Sensitive | Yes |
Olympus launches new SeleCT Screening campaign
- Olympus launches AI-powered emphysema screening program powered by 4DMedical
- SeleCT Screening uses 4DMedical's lung density analysis technology on existing CT scans
- Full market release by Olympus creates large-scale U.S. deployment of 4DMedical's AI-based lung imaging
Olympus Corporation, one of the world's largest medical device companies, has launched a new campaign to accelerate the uptake of SeleCT Screening across the United States. This AI-enabled solution reviews existing CT scans to identify patients with advanced emphysema who may be candidates for bronchoscopic lung volume reduction (BLVR), a minimally invasive intervention using endobronchial valves, such as the Olympus Spiration Valve System. SeleCT Screening represents a large-scale commercial deployment of 4DMedical's AI-based lung density imaging analysis in a therapeutic screening context. The full market release of Olympus' SeleCT Screening program establishes Olympus as a key channel partner, scaling 4DMedical's lung analysis technology across major U.S. health systems, unlocks new patient identification workflows using existing CT infrastructure, and reinforces 4DMedical's expanding clinical utility in early detection, disease stratification, and therapy enablement. Chronic obstructive pulmonary disease (COPD) affects nearly 16 million American adults, with more than 3 million of those diagnosed specifically with emphysema. COPD remains critically under-diagnosed, with studies showing that as many as 80% of adults with COPD worldwide are undiagnosed. This partnership delivers a practical solution to address the global problem of COPD underdiagnosis and expands 4DMedical's presence in interventional respiratory care, an area of significant unmet need and commercial growth opportunities.
This campaign by Olympus represents a significant investment into our partnership with them. Through our combined efforts we are delivering real-world impact at scale--enhancing diagnosis, guiding therapy, and ultimately improving outcomes for patients living with emphysema.